Critical Review on trial of Solanezumab in mild dementia due to Alzheimer’s disease
Added on 2023-04-04
10 Pages2649 Words93 Views
CRITICAL REVIEW ON TRIAL OF SOLANEZUMAB IN MILD
DEMENTIA DUE TO ALZHEIMER’S DISEASE
DEMENTIA DUE TO ALZHEIMER’S DISEASE
INTRODUCTION
The research article titled “Trial of solanezumab for mild dementia due
to Alzheimer’s disease” was done by Lawrence S. Honig, Bruno Vellas,
Michael Woodward, Merce Boada et al. 2129 patients were enrolled for
this study. The article was published in the journal article “THE NEW
ENGLAND JOURNAL OF MEDICINE” in January 25, 2018.
Alzheimer’s disease is a common neurodegenerative disorder with no
effective disease-modifying treatments (Crespi et al., 2015).
Neurofibrillary tangles and amyloid-beta (Aβ) plaques are essential
characteristics for Alzheimer’s disease. Solanezumab is a humanized
monoclonal antibody tested by Eli Lilly, which is a neuroprotecter for
patients suffer with Alzheimer’s disease. Solanezumab binds amyloid-
beta peptides that aggregate and form plaques in the brain. It was
designed to increase the clearance of amyloid-beta peptides from brain
and it leads to the toxic effects in the synapses and leads to the
deposition of amyloid (Honig et al., 2018).
This debilitating illness, which affects quality of life, productivity, and
the economy negatively, affects more than 55 million people globally.
The prevalence of Alzheimer's disease is predicted to rise because of the
growing number of elderly people (Chen, 2018). Although the exact
causes of AD are yet unknown, ageing, environmental, genetic, and
lifestyle variables are all linked to its development. It is believed that the
pathophysiology of AD is associated with the accumulation of beta-
amyloid protein peptides and neurofibrillary tangles (NFT), both of
which cause damage to the neurons (Guo et al., 2020).
The research article titled “Trial of solanezumab for mild dementia due
to Alzheimer’s disease” was done by Lawrence S. Honig, Bruno Vellas,
Michael Woodward, Merce Boada et al. 2129 patients were enrolled for
this study. The article was published in the journal article “THE NEW
ENGLAND JOURNAL OF MEDICINE” in January 25, 2018.
Alzheimer’s disease is a common neurodegenerative disorder with no
effective disease-modifying treatments (Crespi et al., 2015).
Neurofibrillary tangles and amyloid-beta (Aβ) plaques are essential
characteristics for Alzheimer’s disease. Solanezumab is a humanized
monoclonal antibody tested by Eli Lilly, which is a neuroprotecter for
patients suffer with Alzheimer’s disease. Solanezumab binds amyloid-
beta peptides that aggregate and form plaques in the brain. It was
designed to increase the clearance of amyloid-beta peptides from brain
and it leads to the toxic effects in the synapses and leads to the
deposition of amyloid (Honig et al., 2018).
This debilitating illness, which affects quality of life, productivity, and
the economy negatively, affects more than 55 million people globally.
The prevalence of Alzheimer's disease is predicted to rise because of the
growing number of elderly people (Chen, 2018). Although the exact
causes of AD are yet unknown, ageing, environmental, genetic, and
lifestyle variables are all linked to its development. It is believed that the
pathophysiology of AD is associated with the accumulation of beta-
amyloid protein peptides and neurofibrillary tangles (NFT), both of
which cause damage to the neurons (Guo et al., 2020).
SUMMARY:
This research article was written by Lawrence S. Honig et al 2018 to
study the trial of solanezumab for mild dementia due to Alzheimer’s
disease. This study is to discuss the safety and efficacy of the
monoclonal antibody, solanezumab.
The research article's abstract provides an explanation of the study's
outcomes, research methodology, results, and conclusion. This article
did not adhere to the APA style manual's formatting guidelines. The
word limit for an abstract is 250 words, yet this article does not adhere to
the format because it is 342 words long. Furthermore, the writers
neglected to include negative outcomes in the result section. The authors
made an effort to provide all of the study's specifics in the abstract so
that readers would understand it completely..
The phase 3 trials double-blind, placebo-controlled phase is the only set
of results presented in this article. Sample size, trial design, safety
assessment, outcome measure, and adverse events are discussed in the
methods section. The study's age group and diagnostic criteria are easily
understood by the readers. Routine physical and neurologic examination,
clinical laboratory assessment, and collection of adverse event data are
the main safety assessments used for this study.
The primary and secondary efficacies were measured by using different
score scale methods (Delrieu et al., 2022). Only patients with outcome
measurements at and after baseline were included in this analysis. The
experimental procedure and method for data analysis, as well as the
methodological approach employed in the study, have all been
thoroughly discussed.
The statistical significance assessment for the secondary cognitive and
functional measures in this study was not provided because the primary
This research article was written by Lawrence S. Honig et al 2018 to
study the trial of solanezumab for mild dementia due to Alzheimer’s
disease. This study is to discuss the safety and efficacy of the
monoclonal antibody, solanezumab.
The research article's abstract provides an explanation of the study's
outcomes, research methodology, results, and conclusion. This article
did not adhere to the APA style manual's formatting guidelines. The
word limit for an abstract is 250 words, yet this article does not adhere to
the format because it is 342 words long. Furthermore, the writers
neglected to include negative outcomes in the result section. The authors
made an effort to provide all of the study's specifics in the abstract so
that readers would understand it completely..
The phase 3 trials double-blind, placebo-controlled phase is the only set
of results presented in this article. Sample size, trial design, safety
assessment, outcome measure, and adverse events are discussed in the
methods section. The study's age group and diagnostic criteria are easily
understood by the readers. Routine physical and neurologic examination,
clinical laboratory assessment, and collection of adverse event data are
the main safety assessments used for this study.
The primary and secondary efficacies were measured by using different
score scale methods (Delrieu et al., 2022). Only patients with outcome
measurements at and after baseline were included in this analysis. The
experimental procedure and method for data analysis, as well as the
methodological approach employed in the study, have all been
thoroughly discussed.
The statistical significance assessment for the secondary cognitive and
functional measures in this study was not provided because the primary
End of preview
Want to access all the pages? Upload your documents or become a member.
Related Documents
Alzheimer Disease Project PDFlg...
|14
|3441
|143
Systematic Review in Neurosciencelg...
|19
|4643
|30
Herpes Simplex Virus: Researchlg...
|5
|1590
|202
Pathophysiology associated with disorder symptoms: An Alzheimer's patientlg...
|7
|1650
|281
Care for Older People - Case Studylg...
|11
|3312
|26
HNB3209 - Report on Nursing and The Communitylg...
|12
|3009
|98